Grant of fresh 49,712 (Forty-Nine Thousand Seven Hundred Twelve) Employee Stock Options under the existing 'Entero Employee Stock Option Plan 2023'.

Ref: 46/SE/LC/2026-27 Date: November 4, 2026 Scrip Code BSE: 544122 NSE: ENTERO ISIN: INE010601016 Head, Listing Compliance Department H e a d , L i sting Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Mumbai - 400001 Bandra -Kurla Complex, Bandra (East), Mumbai- 400051 Dear Sir/Madam, Subject: Outcome of Board Meeting held on November 4, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved/noted the following: 1) Pursuant to Regulation 33 of the SEBI Listing Regulations, the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, along with Limited Review Reports with an unmodified opinion thereon issued by the Statutory Auditors of the Company, are enclosed as Annexure-A. 2) Pursuant to the approval of the Nomination & Remuneration Committee at its meeting held earlier today, the Board noted the grant of fresh 49,712 (Forty-Nine Thousand Seven Hundred Twelve) Employee Stock Options under the existing “Entero Employee Stock Option Plan 2023”. Details required in terms of Regulation 30 read with Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 are enclosed as Annexure-B. Further to our intimation letter dated September 23, 2026, bearing reference no. 40/SE/LC/2026-27 and pursuant to the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information, framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company, shall open after expiry of 48 hours from the disclosure of financial results. The above intimation is also being made available on the website of the Company at www.enterohealthcare.com The Board Meeting commenced at 02:00 P.M. (IST) and concluded at 06:05 P.M. (IST). You are requested to take the same on record. Yours faithfully, For Entero Healthcare Solutions Limited Sanu Kapoor Vice President- Group General Counsel, Company Secretary & Compliance Officer Annexure-A Enter Entero Healthcare Solutions Limited Registered Office: Plot No. +-36, Building -8, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryand, 121003 Corporate Office: Entero House, Crystal Plaza- 168,C.S.T. Road, Katina, Mumbai-400 098, Maharashtra CIN L74999HR2018PLC072204 TeL. N. 022 26529100 Email: into@enteroheatthcare com Website: www.enterohealthcare.Com Statement of unaudited Standalone Financial Results for the quarter and hatf year ended 30 September 2026 (Rs. in Millon, except per equr ty snhara e data) Quarter ended Half year ended Year ended No Particulars 30 September 2026 30 June 2026 30 September 2025 30 September 2026 30 September 2025 31March 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) ' none )Revenue from operations 1,145.71 832.66 832 21 1,978.37 1,625.73 3,482.41 b)Other income 220.82 231.45 242 25 452.27 505.13 1,13723 Tott incomne 1,366.53 1,064.11 1,074.46 2,430.64 2,130.86 4,619.64 2 Expenses a) Purchase of Stock n-trade 79137 568.13 61296 1.359.50 1.572.09 2.780.65 b) Changes in inventories of Stock n-trade (10.80] 161.05 9480 150.25 (163.43) 356.41 c)Employee benetits expense 161.08 122 94 143 28 284.02 283.06 578.72 d)Finance costs 611 57.42 711 118.53 13.05 46.08 e)Deprecation an amortisation expense 3172 31.07 33.22 6279 61.45 117.22 f Other expenses 88.86 77.45 106.99 166 31 196.90 393.73 Totat Expenses 1,123.34 1,018.06 998.37 2141.40 1,963.13 4,272.81 3 profit before exceptional items and tax (1)-(2) 243.19 46.05 76.09 289.24 16773 346.83 d Exceptional Items 4497 S profit before tax (3)- (4) 243.19 46.05 76.09 289.24 167.73 301.86 6 Tax expenses Current tax (including tax expense of enrtier yeat) 3.04 2.20 18.03 524 18.03 89.06 Deterred tax charge/(credit] 487¥ 9.28 1 10 5799 23.17 (55.95) otat tax expenses 51.75 11.48 19.13 63.23 41.20 33.11 •7 Profit tor the period/year (5)-46) 191.44 34.57 $6.96 226.01 126.53 268.75 Other comprehensive income ltems that will not be reclassified subsequently to profit and loss Remeasurement gain/ (loss)on defined benefit plan 37% (0.94) (1,12 277 (0.73) (3.75) Income tar effect on above (0.94) 0.24 0.28 (0.70 0.18 0.94 Total other comprehensive income 2.7 (0.70) (0.84) 2.07 (0.5$5 (2.81) 9 Totat comprehensive income (7)+ (8) 194.21 33.87 56.12 228.08 125.98 265.94 10 Pai-up equity share capitat (face value Rs 10per share) 435 23 435.23 435.09 435 23 435.09 435.11 11 Other equity 16.395.25 12 Earnings per share (Face value otRs. 10 each) basic-(Rs)' 4.40 079 1.31 519 2.91 6.18 Earrings per share (Face value 0tRs 1peach) diluted -(Rs )' 4.39 0.79 131 5.18 290 6.17 (not annualised for the quarter and half year) See accompanying notes to the unaudited standatone financial results NOTES· The unaudited standalone financial results are prepare in accordance with the recognition and measurement principles provided in Indian Accounting Standard (ind AS 34 on' Interim Financiat Reporting', the provisions ot the Companies Act, 2013 (the Act), an SEBI Circular N. CIRICFD/FAC/62/2016 dated 05 July 2016, as amended. In terms ot Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, s amended, the above unaudited standalone financiat tesutts ot Entero Healthcare Solutions Limite (the Company) have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on4 November 2026. The statutory au0tors ave expressed an unmoved conclusion on these unaudited standalone financat results 2 The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 Operating Segments 3 Duringtne penioene30September2o26, teCompanyhgs subscribetotne Optionally Convertible Debenture[OCD'issuepyits subsidiaries, etaiteastoows Nam otthe entity tritnumbat Date o'issuance lssue pnie Saurashtra Med±solutions Private Limited 36.250 9May 2026 3.300 Sni Parstva Pharma Distributors Private Limited 38 000 274pn4 2026 8400 S.S.Pharma Traders Private Limited 4.000 22 May 2026 55,000 Avenues Pharma Distributors Private Limited 62.500 8 Art 2026 5,600 4 Subsequent to the period ended 30 September 2026, the Company has subscribed to 15,00,000 Optionally Convertibte Debentures (OCD')issued by Chhabra Healthcare Solution Private Limited at Rs. 120 per 0CD on 03 November 2026 During the period ended 3 September 2026, the Company has allotted 12,135 equity shares of Rs.10each at a premium ot Rs. 794 per share aggregating to Rs, 9.76 million pursuant to exercise ot employee stock options 6 During the period ended 30 September 2026, the Company has granted 24,800 employee stock options under Entero Employee Stock Option Ptan 2023 7The above unaudited standalone financial results ot the Company are avaitabte on the website of the Company (www.enteroheatthcare.com) and on the websites ot NSE (www.nseinia.com) and BSE (www.bseindia.com) Entero Healthcare Solutions Limited Entero "'"'" c" r' oo rm at« eo omPlo cot No,0 .1-,3,50 , He ou ,,t ,d . n ,g -�E n �st ,e S c trn "ilo lo H u P 'e l "s» oa t zo 't oh a ° t - 'c 1" "a 5 0r 8e 2_ , 0s~ ;op,n .°8"a P'±"s L"" .e" C o - mn 'o1 °e,s n1 s ' L a , 2im , 0, a 4i t e adu sn ,o r ,sa 4o b" a" t. 4p 0ar 00i d ~ab %.a a 8, d, Ha sry saat n na t. r a, 1 21003 ret No.022""_ enterohea. WEembasiitt: ei.n wto ww.en oheatthcare.con particulars 31March 2026 (Audited) 170.45 1715 18249 21415 74.62 810 8.658 76 +64993 5.342.99 5.726.63 11751 84.60 62 22 120.91 15566 201.64 961 9 14,821.30 14,287.60 58309 733 34 43444 596 03 94453 103466 259.43 56763 20.00 34 2828.66 [Showing first 8,000 characters — download PDF for full document]